New targeted drug shows promise for rare gene-driven cancers
Disease control
Recruiting now
This study tests an experimental drug called lirafugratinib in adults with advanced solid tumors (except bile duct cancer) that have a specific FGFR2 gene fusion or rearrangement. Participants take the drug by mouth and visit the clinic for regular checkups. The goal is to see if…
Phase: PHASE2 • Sponsor: Elevar Therapeutics • Aim: Disease control
Last updated May 07, 2026 18:38 UTC